Clinicopathological Profile of Low-Grade B Cell Non-Hodgkin Lymphoma in Tertiary Health Care in West Java Indonesia
Background: Low-grade B cell Non-Hodgkin lymphomas (NHL) are a group of lymphomas that are predominantly indolent and make up approximately 50% of all malignant lymphomas. Initial therapy for low-grade B cell LNH has an overall response rate of between 85-94% and a refractory rate of 6-10%. Few reports have been published regarding the clinicopathological characteristics of non-Hodgkin lymphoma cases, especially low-grade B cell types. This research aims to determine the clinicopathological profile of low-grade B cell type non-Hodgkin lymphoma cases.
Method: This research is a descriptive study using cross-sectional methods. The sample consisted of 40 low-grade B cell type NHL cases from January 2015 to June 2020 at Hasan Sadikin Hospital, Bandung. Clinicopathological data, including age, sex, location of the tumor (nodal or extranodal), stage, B symptoms, and response to therapy, were taken from the patients’ medical records. Data were categorized into 2 groups based on response to initial therapy.
Results and Discussion: Of the 40 cases diagnosed with low-grade B cell type NHL, 55% responded to initial therapy. From the non-response group, 61.1% were stage II and 72.2% exhibited B symptoms. There were no significant differences in age, sex, tumor location (nodal or extranodal), stage, or B symptoms in the response and non-response groups.
Conclusion: In this study, 45% of patients with low-grade B cell type NHL did not respond to initial therapy. There was no statistically significant difference in the clinicopathological profiles of the response and non-response groups to initial therapy in cases of low-grade B cell type NHL.
Keywords: Non-Hodgkin Lymphoma, low-grade B cell lymphoma, therapy response, clinicopathological
2. Piñeros M, ZNaor A, Marcos-Gragera R, Steliarova-Foucher E. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer causes & control. 2019 May; 30(5):489–99.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018 Nov 1; 68(6):394–424.
4. The Global Cancer Observatory. Indonesia Population Fact Sheet [Internet]. IARC WHO; 2018. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
5. Cömert P, Yıldız A, Yıldırım M, Afacan Öztürk HB, Pala Ç, Albayrak M, et al. Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. Indian Journal of Hematology and Blood Transfusion. 2019 Aug 6; Available from: https://doi.org/10.1007/s12288-019-01168-9
6. Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. American Journal of Hematology. 2018 Feb 1;93(2):296–305.
7. Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. American Journal of Hematology. 2019 Jun 1; 94(6):710–25.
8. Bron D, Meuleman N. Marginal zone lymphomas: second most common lymphomas in older patients. Current opinion in oncology. 2019; 31(5):386–93.
9. Kang J, Hong JY, Suh C. Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. Blood Res. 2018 Sep; 53(3):18997.
10. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):326–62.
11. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, et al. NCCN Guidelines Version 4.2019 B cell Lymphoma. National Comprehensive Cancer Network; 2019. Available from: www.nccn.org
12. Ninkovic S, Lambert J. Non-Hodgkin lymphoma. Medicine. 2017 May; 45(5):297–304.
13. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016/06/27 ed. 2016 Oct; 101(10):1244–50.
14. Ciobanu A, Stanca O, Triantafyllidis I, Lupu A. Indolent lymphoma: diagnosis and prognosis in medical practice. Maedica (Bucur). 2013 Sep; 8(4):338–42.
15. Mukkamalla S, Taneja A, Malipeddi D. Chronic Lymphocytic Leukemia. In: StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/
16. Sharma R, Cunningham D, Smith P, Robertson G, Dent O, Clarke SJ. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer. 2009 May 18; 9:153–153.
17. Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. British Journal of Haematology [Internet]. 2019 Dec 2. Available from: https://doi.org/10.1111/bjh.16264
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).